Inhibrx Biosciences, Inc. (INBX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $108.19 (+3.30%), Market cap $1.59B, 52-week low–high $12.47 ~ $141.84.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc.
Financial statements, price targets, institutional (13F) holdings and related news for Inhibrx Biosciences, Inc. are updated in real time on BlackAll Trade.
Inhibrx Biosciences, Inc. trades at $108.19 (+3.30%). Real-time quotes and charts are available on BlackAll Trade.
Inhibrx Biosciences, Inc. has a market cap of about $1.59B.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates inclu